

# PRESS RELEASE

innate pharma

## INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FULL YEAR 2021 FINANCIAL RESULTS

**Marseille, France, March 17, 2022, 7:00 AM CET**

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("**Innate**" or the "**Company**"), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m. ET, following the release of its financial results for the full year ending December 31, 2021.

Speakers during the call will be:

- Mondher Mahjoubi, Chief Executive Officer
- Joyson Karakunnel, Executive Vice President, Chief Medical Officer
- Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development
- Frédéric Lombard, Senior Vice President, Chief Financial Officer

### **Details for the Virtual Event**

The live webcast will be available at the following link:

<https://event.on24.com/wcc/r/3577447/6B0C866D3C3BB7A70F1BAAD02F7320D2>.

Participants may also join via telephone using the dial-in details below:

France: 0805 620 704  
United States: 1 844 200 6205 / 1 646 904 5544  
United Kingdom: 44 208 0682 558 / 44 808 189 648  
All other locations: +1 929 526 1599

**Access code: 834852**

This information can also be found on the Investors section of the Innate Pharma website, [www.innate-pharma.com](http://www.innate-pharma.com). A replay of the webcast will be available on the Company website for 90 days following the event.


### **About Innate Pharma:**

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.



# PRESS RELEASE

innate pharma

---

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com)

## Information about Innate Pharma shares:

**ISIN code** FR0010331421  
**Ticker code** Euronext: IPH Nasdaq: IPHA  
**LEI** 9695002Y8420ZB8HJE29

## Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts, the Company's continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company's business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website <http://www.amf-france.org> or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

## For additional information, please contact:

### Investors and Media

**Innate Pharma**  
Henry Wheeler  
Tel.: +33 (0)4 84 90 32 88  
[Henry.wheeler@innate-pharma.fr](mailto:Henry.wheeler@innate-pharma.fr)

**ATCG Press**  
Marie Puvieux (France)  
Tel.: +33 981 87 46 72  
[innate-pharma@atcg-partners.com](mailto:innate-pharma@atcg-partners.com)